Correction To: Anti‑PD‑1 Antibody‑activated Th17 Cells Subvert Re‑invigoration of Antitumor Cytotoxic T‑lymphocytes Via Myeloid Cell‑derived COX‑2/PGE2.
Cancer Immunology and Immunotherapy(2022)
摘要
Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint inhibitor therapy in the LSL-KrasG12D murine lung cancer model. Herein, we establish that the Th17 subset is the primary driver of resistance to therapy demonstrate that the ontogeny of dysplasia-associated Th17 cells is driven by microbiota-conditioned macrophages; and identify the IL-17-COX-2-PGE2 axis as the mediator of CD8+ cytotoxic T-lymphocyte de-sensitization to checkpoint inhibitor therapy. Specifically, anti-PD-1 treatment of LSL-KrasG12D mice, in which CD4+ T-cells were deficient for RORc, resulted in a 60
更多查看译文
关键词
Anti-PD-1 resistance,NSCLC,Th17 cell,Lung microbiota,COX-2,PGE2
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要